Trading Statement

DXS International

17/05/2023 12:14

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230517:nGNE88mVCp&default-theme=true


DXS INTERNATIONAL PLC

(AQSE: DXSP)

Trading Update – May 2023

DXS International plc ("DXS" or the "Company"), the digital clinical decision
support company, is pleased to provide shareholders with a trading update.

The company expects revenue for the year ending April 2023 to be £3.3
million, marginally up on April 2022, with a very small profit after tax.

With the NHS largely inaccessible from a sales and marketing perspective, the
company has during the past three years used this time to pilot new
sophisticated SaaS solutions. Based on feedback from the various pilots, the
company has enhanced the solutions, gained additional NHS IM1 accreditation,
attained MHRA certification (required for software classed as medical devices)
and planned the sales and marketing strategy for the financial year ahead.

As the NHS recovery kicks in, the company has - as announced earlier today -
raised £500,000 at a price of 4 pence per share through Hybridan LLP acting
as sole broker, to be used mainly for immediate sales and marketing
initiatives, and to continue to drive revenue growth and profitability. These
initiatives will focus on:

•        Leveraging off our existing 2,000 GP practices user base.

•        Targeting new greenfield prospects with convertible free
trial offers.

These initiatives will build on our current two key solutions, one existing
with new SMART referral ability and the other our new Hypertension solution.
With both these solutions demonstrating powerful Return on Investment (ROI) to
both healthcare clinicians and the NHS, these sales initiatives are
underpinned by compelling and measurable ROI.

In the next 11 months, we have the building blocks in place to potentially
rapidly scale our annual revenue to £4.7m by April 2024, from £3.3m April
2023. We intend to achieve this via a combination of growing existing
pharmaceutical income of £1.5 million by 8% p.a., and increasing our existing
NHS revenue by 27% from £1.8m to £2.3m, of which we already have
approximately 16% (which represents 60% of the increase) under discussion.

We intend to supplement this with additional revenue from our new hypertension
medicine optimisation product, adding approximately £130,000 of new revenue
from SMART Pathways, and generating new revenue of approximately £700,000
from the ExpertCare Hypertension solution. DXS has entered into an agreement
with Deontics Limited to use its AI Technology to enable the growth in the
revenue from NHS SMART Referral and SMART Pathways.

In addition, while not expected to be revenue generating within the next 12
months, we plan our entry into the USA. This will be via a recent bid won by
DXS to conduct a hypertension trial with North Western Medicine in Chicago.

A copy of our latest investor presentation can be found on the Company
website.

David Immelman, CEO of DXS International plc, commented:

“I am delighted with the continued support we have received from our
shareholders, and to welcome new institutions including funds managed by
Downing LLP in this latest fundraising. We are pleased to see sentiment
changing within the NHS and to hear the positive feedback we have received on
the various trials in clinics with our new products. Building blocks are in
place to potentially rapidly scale our annual revenue to £4.7m by April
2024.”

The Directors of DXS International plc accept responsibility for this
announcement

The information contained within this announcement is deemed to constitute
inside information as stipulated under the retained EU law version of the
Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018. The information is
disclosed in accordance with the Company's obligations under Article 17 of the
UK MAR. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

Enquiries:

 David Immelman (Chief Executive) DXS International plc  01252 719800 david@dxs-systems.com  
 https://www.dxs-systems.co.uk                                                               



 Corporate Advisor                              
 City & Merchant David Papworth  020 7101 7676  



 Corporate Broker                                 
 Hybridan LLP Claire Louise Noyce  020 3764 2341  

Note to Editors:

About DXS

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses, and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively
which should significantly contribute towards the NHS achieving its projected
efficiency savings